Scl 70 Antibodies, IgG, Serum
Use
Evaluating patients with clinical features of systemic sclerosis and in the differential evaluation of individuals at-risk for connective tissue disease with Hep-2 substrate antinuclear antibody positive result. Antibody to Scl 70 is considered specific for systemic sclerosis (SSc) and is typically associated with diffuse cutaneous SSc, which is characterized by disease severity including musculoskeletal, cardiac involvement, and interstitial lung disease. It is also associated with a positive antinuclear antibody (ANA) when tested with the HEp-2 substrate using the indirect immunofluorescence assay (IFA). Clinical context and correlation with positive ANA test using HEp-2 is crucial for proper interpretation.
Special Instructions
Not provided.
Limitations
The presence of Scl 70 antibodies has a high degree of specificity for systemic sclerosis but the assays could show discrepancies due to different detection methods. Discrepancies between anti-Scl-70 antibody assays can impact clinical care, particularly in patients with interstitial lung disease. Low positive Scl 70 antibody results can be present in other inflammatory conditions, such as systemic lupus erythematosus, necessitating cautious interpretation. Performance characteristics of individual assays may vary, with some assays being less specific compared to traditional immunodiffusion methods.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
Scl 70
Protein
LOINC Codes
- 47322-3 - ENA Scl70 IgG Ser IA-aCnc
- 47322-3 - ENA Scl70 IgG Ser IA-aCnc
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.4 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis, Gross lipemia, Heat-Treated
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 21 days |
| Frozen | 21 days |